The importance of fatty liver disease in clinical practice (Q37766943)

22 August 2017

1 reference

title

The importance of fatty liver disease in clinical practice (English)

1 reference

22 August 2017

0 references

1 reference

Simon D Taylor-Robinson

series ordinal

3

object named as

Simon D Taylor-Robinson

1 reference

22 August 2017

Jeremy F L Cobbold

1

1 reference

PubMed ID

20569523

22 August 2017

Quentin M Anstee

series ordinal

2

1 reference

22 August 2017

23 June 2010

1 reference

Proceedings of the Nutrition Society

22 August 2017

1 reference

22 August 2017

69

1 reference

22 August 2017

518-527

1 reference

22 August 2017

4

1 reference

Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study

22 August 2017

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Fructose consumption as a risk factor for non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Choline: an essential nutrient for public health

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

An unexpected requirement for phosphatidylethanolamine N-methyltransferase in the secretion of very low density lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Biochemical and evolutionary significance of phospholipid methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Fish oil prevents insulin resistance induced by high-fat feeding in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

AGA technical review on nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

The natural history of nonalcoholic fatty liver disease: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

The plasma lipidomic signature of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): a cross-sectional study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Phenotyping murine models of non-alcoholic fatty liver disease through metabolic profiling of intact liver tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Maternal high-fat feeding primes steatohepatitis in adult mice offspring, involving mitochondrial dysfunction and altered lipogenesis gene expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Pathogenesis of steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Mouse models in non-alcoholic fatty liver disease and steatohepatitis research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Recent advances in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Steatohepatitis: a tale of two "hits"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Quantification of liver fat content: comparison of triple-echo chemical shift gradient-echo imaging and in vivo proton MR spectroscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Hepatic lipid profiling in chronic hepatitis C: an in vitro and in vivo proton magnetic resonance spectroscopy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Insulin resistance: a metabolic pathway to chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

The metabolic syndrome--a new worldwide definition

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Liver fat content and T2*: simultaneous measurement by using breath-hold multiecho MR imaging at 3.0 T--feasibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Non-invasive means of measuring hepatic fat content.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Is oil red-O staining and digital image analysis the gold standard for quantifying steatosis in the liver?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Dietary fructose reduces circulating insulin and leptin, attenuates postprandial suppression of ghrelin, and increases triglycerides in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Endocrine and metabolic effects of consuming beverages sweetened with fructose, glucose, sucrose, or high-fructose corn syrup

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

How different is the dietary pattern in non-alcoholic steatohepatitis patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

Sex and menopausal status influence human dietary requirements for the nutrient choline

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

7 January 2021

Omega-3 fatty acids and liver disease

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

7 January 2021

Dietary (n-3) long chain polyunsaturated fatty acids prevent sucrose-induced insulin resistance in rats

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

7 January 2021

Rising incidence of hepatocellular carcinoma in the United States

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

7 January 2021

Prolonged saturated fat-induced, glucose-dependent insulinotropic polypeptide elevation is associated with adipokine imbalance and liver injury in nonalcoholic steatohepatitis: dysregulated enteroadipocyte axis as a novel feature of fatty liver

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

7 January 2021

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

7 January 2021

Association of cardiorespiratory fitness, body mass index, and waist circumference to nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

7 January 2021

The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

7 January 2021

Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

7 January 2021

A position statement on NAFLD/NASH based on the EASL 2009 special conference

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

7 January 2021

Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis.

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

7 January 2021

Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

7 January 2021

Nonalcoholic steatosis and steatohepatitis. III. Peroxisomal beta-oxidation, PPAR alpha, and steatohepatitis

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

7 January 2021

Nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1017%2FS0029665110001916

7 January 2021

10.1017/S0029665110001916

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20569523